Hormone Replacement Therapies and Other Hormone Therapies: Global Markets

Table of Contents

Hormone Replacement Therapies and Other Hormone Therapies: Global Markets

• SUMMARY TABLE SALES FOR THE HORMONE REPLACEMENT AND OTHER THERAPIES, THROUGH 2013 ($ MILLIONS)
• SUMMARY FIGURE SALES FOR THE HORMONE REPLACEMENT AND OTHER THERAPIES, 2006-2013 ($ MILLIONS)

• HORMONES
• DEFINITIONS
• Hormone
• Peptide
• Metabolism
• INTRODUCTION
• Classification of Hormones
• Anatomical Source of the Hormone
• Hypothalamic Hormones
• Posterior Pituitary Hormone
• Anterior Pituitary Hormone
• Thyroid Hormones
• Parathyroid Hormones
• Cardiac Hormones
• Adrenal Cortical Hormones
• Adrenal Medullary Hormones
• Kidney Hormones
• Pancreatic Hormones
• Liver Hormones
• Digestive Hormones
• Gonadal Hormones
• Gonadal Hormones (Continued)
• Pineal Hormones
  • TABLE 1 ANATOMICAL CLASSIFICATION OF HORMONES
• Chemical Classification
• Peptide Hormones
• Amine hormones
• Steroid Hormones
  • TABLE 2 CHEMICAL CLASSIFICATION OF HORMONES
• HORMONE THERAPY
• DEFINITION

• ESTROGEN THERAPY
  • TABLE 3 DRUG PRODUCTS USED IN ESTROGEN THERAPY
• PROGESTERONE/ESTROGEN THERAPY
  • TABLE 4 DRUG PRODUCTS USED IN ESTROGEN/PROGESTERONE COMBINATION THERAPY
• PROGESTERONE THERAPY
  • TABLE 5 DRUG PRODUCTS USED IN PROGESTERONE THERAPY
• RECOMBINANT GROWTH HORMONE THERAPY
  • TABLE 6 DRUG PRODUCTS USED IN RECOMBINANT GROWTH HORMONES
• THYROID HORMONE THERAPY
  • TABLE 7 DRUG PRODUCTS USED IN THYROID HORMONE THERAPY
  • TABLE 7 (CONTINUED)
• TESTOSTERONE REPLACEMENT THERAPY
  • TABLE 8 DRUG PRODUCTS USED IN TESTOSTERONE REPLACEMENT THERAPY
• SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS)
  • TABLE 9 DRUG PRODUCTS USED IN SELECTIVE ESTROGEN RECEPTOR MODULATORS
• ANTIESTROGEN THERAPY
  • TABLE 10 DRUG PRODUCTS USED IN ANTIESTROGENS
• ANTIANDROGEN THERAPY
  • TABLE 11 DRUG PRODUCTS USED IN ANTIANDROGEN THERAPY
• AROMATASE INHIBITOR THERAPY
  • TABLE 12 DRUG PRODUCTS USED IN AROMATASE INHIBITOR THERAPY
• LUTEINIZING HORMONE-RELEASING HORMONE
  • TABLE 13 DRUG PRODUCTS USED AS LUTEINIZING HORMONE-RELEASING HORMONE (LH RH)

• MENOPAUSE
• MENOPAUSE AND HORMONE THERAPY
• OSTEOPOROSIS
• OSTEOPOROSIS AND HORMONE THERAPY
• CANCER
• CANCER AND HORMONE THERAPY
• GROWTH HORMONE DEFICIENCIES
• GROWTH HORMONE DEFICIENCY AND HORMONE THERAPY
• TURNER' S SYNDROME
• TURNER' S SYNDROME AND HORMONE THERAPY
• KLINEFELTER SYNDROME
• KLINEFELTER SYNDROME AND HORMONE THERAPY
• THYROID HORMONE DISORDER: HYPOTHYROIDISM
• HYPOTHYROIDISM AND HORMONE THERAPY
• MALE HYPOGONADISM
• MALE HYPOGONADISM AND HORMONE THERAPY
• NOONAN SYNDROME
• NOONAN SYNDROME AND HORMONE THERAPY
• SHORT BOWEL SYNDROME (SBS)
• SBS AND HORMONE THERAPY
• PRADER-WILLI SYNDROME
• PRADER-WILLI SYNDROME AND HORMONE THERAPY
• GOITER
• GOITER AND HORMONE THERAPY

• NEW DRUG APPROVALS
  • TABLE 14 HORMONE THERAPY DRUGS APPROVED BY FDA (2005 TO JUNE 2008)
• ALL TYPES OF APPROVALS
  • TABLE 15 HORMONE THERAPY ALL TYPES OF APPROVALS BY FDA (2005 TO JUNE 2008)
  • TABLE 15 (CONTINUED)
  • TABLE 15 (CONTINUED)
• NEW DRUG APPLICATIONS
  • TABLE 16 NEW DRUG APPLICATIONS (2005 TO JUNE 2008)
• RECALLS AND SAFETY ALERTS
  • TABLE 17 RECALLS AND SAFETY ALERTS (2005 TO JUNE 2008)

• ESTROGEN REPLACEMENT THERAPY
• ESTROGEN (ALONE)
  • TABLE 18 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ESTROGEN (ALONE) THERAPY, 2007 (%)
  • FIGURE 1 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ESTROGEN REPLACEMENT THERAPY, 2007 (%)
• ESTROGEN/PROGESTERONE
  • TABLE 19 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR COMBINATION (ESTROGEN/PROGESTERONE) THERAPY, 2007 (%)
  • FIGURE 2 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR COMBINATION (ESTROGEN/PROGESTERONE) THERAPY, 2007 (%)
• RECOMBINANT GROWTH HORMONE THERAPY
  • TABLE 20 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR RECOMBINANT GROWTH HORMONE THERAPY, 2007 (%)
  • FIGURE 3 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR RECOMBINANT GROWTH HORMONE THERAPY, 2007 (%)
• THYROID HORMONE THERAPY
  • TABLE 21 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR THYROID HORMONE THERAPY, 2007 (%)
  • FIGURE 4 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR THYROID HORMONE THERAPY, 2007 (%)
• TESTOSTERONE HORMONE THERAPY
  • TABLE 22 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR TESTOSTERONE HORMONE THERAPY, 2007 (%)
  • FIGURE 5 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR TESTOSTERONE HORMONE THERAPY, 2007 (%)
• ANTIESTROGENS AND SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERM)
  • TABLE 23 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ANTIESTROGENS AND SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2007 (%)
  • FIGURE 6 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ANTIESTROGENS AND SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2007 (%)
• ANTIANDROGENS
  • TABLE 24 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ANTIANDROGENS, 2007 (%)
  • FIGURE 7 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ANTIANDROGENS, 2007 (%)
• AROMATASE INHIBITORS
  • TABLE 25 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR AROMATASE INHIBITORS, 2007 (%)
  • FIGURE 8 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR AROMATASE INHIBITORS, 2007 (%)
• LUTEINIZING HORMONE RELEASING HORMONE (LHRH) AGONISTS
  • TABLE 26 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR LH RH AGONISTS, 2007 (%)
  • FIGURE 9 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR LH RH AGONISTS, 2007 (%)

• KEY MARKET RESTRAINTS
• COMPETITION
• PATENT EXPIRATION
  • TABLE 27 SIGNIFICANT PATENT EXPIRIES
• COST OF HRT DRUGS
• LOW AWARENESS
• KEY MARKET DRIVERS
• NEW DRUG DELIVERY TECHNOLOGIES
• GROWING AWARENESS
• AGING OF THE POPULATION
• RETURNING CONFIDENCE IN HRT
• BENEFITS OF HRT OVER NON-HORMONAL DRUGS
• LIFE EXPECTANCY
• DTC (DIRECT TO CONSUMER) ADVERTISING
• STRATEGIES OF MANUFACTURERS
• Strategies of Manufacturers (Continued)

• MARKET SIZE
  • TABLE 28 WORLDWIDE SALES OF HORMONE THERAPIES, THROUGH 2013 ($ MILLIONS)
  • FIGURE 10 WORLDWIDE SALES OF HORMONE THERAPIES, 2006-2013 ($ MILLIONS)
  • TABLE 29 WORLDWIDE SHARE OF HORMONE THERAPIES, 2007
  • FIGURE 11 WORLDWIDE SHARE OF HORMONE THERAPIES, 2007 (%)
• ESTROGEN REPLACEMENT THERAPY
• Market Outlook
• ESTROGEN
• Market Size
  • TABLE 30 GLOBAL SALES OF ESTROGEN (ALONE) THERAPY, THROUGH 2013 ($ MILLIONS)
  • FIGURE 12 WORLDWIDE SALES OF ESTROGEN (ALONE) THERAPY, 2006-2013 ($ MILLIONS)
• COMBINATION THERAPY (ESTROGEN/ PROGESTERONE)
• Market Size
  • TABLE 31 GLOBAL SALES OF COMBINATION THERAPY (ESTROGEN/PROGESTERONE), THROUGH 2013 ($ MILLIONS)
  • FIGURE 13 WORLDWIDE SALES OF COMBINATION THERAPY (ESTROGEN/PROGESTERONE), 2006-2013 ($ MILLIONS)
• RECOMBINANT GROWTH HORMONE THERAPY
• Market Outlook
• Market Size
  • TABLE 32 GLOBAL SALES OF RECOBINANT GROWTH HORMONE THERAPY THROUGH 2013 ($ MILLIONS)
  • FIGURE 14 WORLDWIDE SALES OF RECOMBINANT GROWTH HORMONE THERAPY, 2006-2013 ($ MILLIONS)
• THYROID HORMONE THERAPY
• Market Outlook
• Market Size
  • TABLE 33 GLOBAL SALES OF THYROID HORMONE THERAPY, THROUGH 2013 ($ MILLIONS)
  • FIGURE 15 WORLDWIDE SALES OF THYROID HORMONE THERAPY, 2006-2013 ($ MILLIONS)
• TESTOSTERONE HORMONE THERAPY
• Market Outlook
• Market Size
  • TABLE 34 GLOBAL SALES OF TESTOSTERONE HORMONE THERAPY, THROUGH 2013 ($ MILLIONS)
  • FIGURE 16 WORLDWIDE SALES OF TESTOSTERONE HORMONE THERAPY, 2006-2013 ($ MILLIONS)
• ANTIESTROGENS AND SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERM)
• Market Outlook
• Market Size
  • TABLE 35 GLOBAL SALES OF ANTIESTROGEN AND SELECTIVE ESTROGEN RECPTOR MODULATORS, THROUGH 2013 ($ MILLIONS)
  • FIGURE 17 WORLDWIDE SALES OF ANTIESTROGEN AND SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2006-2013 ($ MILLIONS)
• ANTIANDROGEN THERAPY
• Market Outlook
• Market Size
  • TABLE 36 GLOBAL SALES OF ANTIANDROGEN THERAPY, THROUGH 2013 ($ MILLIONS)
  • FIGURE 18 WORLDWIDE SALES OF ANTIANDROGEN THERAPY, 2006-2013 ($ MILLIONS)
• AROMATASE INHIBITORS
• Market Outlook
• Market Size
  • TABLE 37 GLOBAL SALES OF AROMATASE INHIBITORS, THROUGH 2013 ($ MILLIONS)
  • FIGURE 19 WORLDWIDE SALES OF AROMATASE INHIBITORS, 2006-2013 ($ MILLIONS)
• LUTEINIZING HORMONE-RELEASING HORMONE (LH RH) AGONISTS
• Market Outlook
• Market Size
  • TABLE 38 GLOBAL SALES OF LH RH AGONISTS, THROUGH 2013 ($ MILLIONS)
  • FIGURE 20 WORLDWIDE SALES OF LH RH AGONIST, 2006-2013 ($ MILLIONS)
• New Developments
  • TABLE 39 CLINICAL TRIALS IN THE ESTROGEN REPLACEMENT THERAPY
  • TABLE 39 (CONTINUED)
  • TABLE 40 CLINICAL TRIALS IN THE PROGESTEROEN THERAPY
  • TABLE 40 (CONTINUED)
  • TABLE 41 CLINICAL TRIALS IN THYROID HORMONE THERAPY
  • TABLE 42 CLINICAL TRIALS IN TESTOSTERONE REPLACEMENT THERAPY
  • TABLE 42 (CONTINUED)
  • TABLE 43 CLINICAL TRIALS IN RECOMBINANT GROWTH HORMONE
  • TABLE 43 (CONTINUED)
  • TABLE 44 CLINICAL TRIALS IN ANTIESTROGEN THERAPY
  • TABLE 44 (CONTINUED)
  • TABLE 44 (CONTINUED)
  • TABLE 45 CLINICAL TRIALS IN ESTROGEN RECEPTOR MODULATORS
  • TABLE 46 CLINICAL TRIALS IN ANTIANDROGEN THERAPY
  • TABLE 47 CLINICAL TRIALS IN AROMATASE INHIBITORS
  • TABLE 48 CLINICAL TRIALS IN LH RH AGONISTS

• TABLE 49 GLOBAL SALES OF HORMONE THERAPY BY TYPE OF DISEASE, THROUGH 2013 ($ MILLIONS)
• FIGURE 21 GLOBAL SALES OF HORMONE THERAPY BY TYPE OF DISEASE, 2006-2013 ($ MILLIONS)
• TABLE 50 MARKET SHARE OF VARIOUS TYPES OF DISEASES, 2007 (%)
• FIGURE 22 MARKET SHARE OF VARIOUS TYPES OF DISEASES, 2007 (%)
• MENOPAUSE
  • TABLE 51 GLOBAL SALES OF HRT IN MENOPAUSE MARKET, THROUGH 2013 ($ MILLIONS)
  • FIGURE 23 GLOBAL SALES OF HRT IN MENOPAUSE MARKET, 2006-2013 ($ MILLIONS)
• OSTEOPOROSIS
  • TABLE 52 GLOBAL SALES OF HRT IN OSTEOPOROSIS MARKET, THROUGH 2013 ($ MILLIONS)
  • FIGURE 24 GLOBAL SALES OF HRT IN OSTEOPOROSIS MARKET, 2006-2013 ($ MILLIONS)
• HYPOTHYROIDISM
  • TABLE 53 GLOBAL SALES OF HRT IN HYPOTHYROID MARKET, THROUGH 2013 ($ MILLIONS)
  • FIGURE 25 GLOBAL SALES OF HRT IN HYPOTHYROID MARKET, 2006-2013 ($ MILLIONS)
• MALE HYPOGONADISM
  • TABLE 54 GLOBAL SALES OF HRT IN THE MALE HYPOGONADISM MARKET, THROUGH 2013 ($ MILLIONS)
  • FIGURE 26 GLOBAL SALES OF HRT IN THE MALE HYPOGINADISM MARKET, 2006-2013 ($ MILLIONS)
• KLINEFELTER SYNDROME
  • TABLE 55 GLOBAL SALES OF HRT IN KLINEFELTER SYNDROME MARKET, THROUGH 2013 ($ MILLIONS)
  • FIGURE 27 GLOBAL SALES OF HRT IN KLINEFELTER SYNDROME MARKET, 2006-2013 ($ MILLIONS)
• TURNER' S SYNDROME
  • TABLE 56 GLOBAL SALES OF HRT IN TURNER' S SYNDROME MARKET, THROUGH 2013 ($ MILLIONS)
  • FIGURE 28 GLOBAL SALES OF HRT IN TURNER' S SYNDROME MARKET, 2006-2013 ($ MILLIONS)
• GROWTH HORMONE DEFICIENCY
  • TABLE 57 GLOBAL SALES OF HRT IN GROWTH HORMONE DEFICIENCY MARKET, THROUGH 2013 ($ MILLIONS)
  • FIGURE 29 GLOBAL SALES OF HRT IN GROWTH HORMONE DEFECIENCY MARKET, 2006-2013 ($ MILLIONS)
• CANCER
  • TABLE 58 GLOBAL SALES OF HRT IN CANCER MARKE, THROUGH 2013 ($ MILLIONS)
  • FIGURE 30 GLOBAL SALES OF HRT IN CANCER MARKET, 2006-2013 ($ MILLIONS)

• TOTAL PATENTS
• PATENTS BY YEAR
  • TABLE 59 TOTAL NUMBER OF PATENTS IN EACH YEAR, 2005 - 2008
  • FIGURE 31 NUMBER OF PATENTS, 2005-2008
• PATENTS BY TYPE
  • TABLE 60 NUMBER OF PATENTS BY TYPE, 2005-2008
  • FIGURE 32 NUMBER OF PATENTS BY TYPE, 2005-2008
  • FIGURE 33 NUMBER OF PATENTS, SHARE BY TYPE OF HORMONE, 2005-2008 (%)
  • FIGURE 33 (CONTINUED)
• PATENTS BY COUNTRY
  • TABLE 61 TOTAL NUMBER OF PATENTS BY COUNTRY, 2005-2008
  • FIGURE 34 TOTAL NUMBER OF PATENTS BY COUNTRY, 2005-2008
• PATENTS BY COMPANY
  • TABLE 62 NUMBER OF PATENTS BY COMPANY, 2005-2008
  • FIGURE 35 NUMBER OF PATENTS BY COMPANY, 2005-2008
• PATENTS BY ASSIGNEE
  • TABLE 63 NUMBER OF PATENTS BY ASSIGNEE TYPE, 2005 - 2008
  • FIGURE 36 NUMBER OF PATENTS BY ASSIGNEE, 2005 - 2008

• TABLE 64 LEADING BRANDED DRUGS IN VARIOUS HORMONE THERAPIES
• CURRENT AND FUTURE HORMONE.....(CONTINUED)

• ABBOTT LABORATORIES INC.
• ACRUX LIMITED
• ASCEND THERAPEUTICS
• ASTRAZENECA PLC
• AUXILIUM PHARMACEUTICALS, INC.
• BARR PHARMACEUTICALS, INC.
• BAYER SCHERING PHARMA AG
• BIOSANTE PHARMACEUTICALS
• CANGENE CORPORATION
• COLUMBIA LABORATORIES, INC.
• ELI LILLY & CO.
• EMD SERONO, INC.
• FERRING PHARMACEUTICALS
• GALEN LTD.
• GENENTECH
• GENESCIENCE PHARMACEUTICALS INC.
• IMPAX LABORATORIES, INC.
• INDEVUS PHARMECEUTICALS, INC.
• IPSEN SA
• JHP PHARMACEUTICALS
• KING PHARMACEUTICALS, INC.
• KV PHARMACEUTICALS
• MYLAN, INC.
• NOVARTIS
• NOVO NORDISK
• NYCOMED U.S.
• ORION CORPORATION
• PADDOCK LABORATORIES, INC.
• PAR PHARMACEUTICAL COMPANIES, INC.
• PFIZER INC.
• SANOFI AVENTIS
• SOLVAY PHARMACEUTICALS
• SYNERX PHARMA
• UNIGENE LABORATORIES, INC.
• UNIMED PHARMACEUTICALS, INC.
• WARNER CHILCOTT
• WATSON LABS
• WYETH

• ABBREVIATIONS
• ABBREVIATIONS (CONTINUED)